Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
The analysis of vitamin D revealed a significant decrease after CBZ treatment (mean ± SD= 36.6 ± 15.68 nmol/L) compared to pre-treatment (45 ± 23.25 nmol/L) with a 95% CI of -14.47 to -2.37 and P = 0.007.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
An observational study involving 226 patients was conducted at King Abdulaziz Medical City in Jeddah, Saudi Arabia.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Long-term effects of carbamazepine on bone-related biochemical markers in patients with epilepsy
Study design awaiting verification · Acta Epileptologica · 2026
Original publication title
Long-term effects of carbamazepine on bone-related biochemical markers in patients with epilepsy
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Carbamazepine (CBZ) is a commonly prescribed antiseizure medication frequently prescribed for epilepsy, trigeminal neuralgia, and mood disorders. However, CBZ is a strong inducer of cytochrome P450 enzymes, which can accelerate the catabolism of vitamin D and potentially alter bone metabolism. This study aimed to evaluate the effects of long-term CBZ administration on bone health in patients with epilepsy.
Source: BackgroundAbstract: What methods does the paper describe?
An observational study involving 226 patients was conducted at King Abdulaziz Medical City in Jeddah, Saudi Arabia. We analyzed the pre: and post-treatment serum levels of vitamin D (nmol/L), alkaline phosphatase (U/L), sodium (mmol/L), and calcium (mmol/L) to assess biochemical changes associated with prolonged CBZ therapy.
Source: MethodsAbstract: Results
The analysis of vitamin D revealed a significant decrease after CBZ treatment (mean ± SD= 36.6 ± 15.68 nmol/L) compared to pre-treatment (45 ± 23.25 nmol/L) with a 95% CI of -14.47 to -2.37 and P = 0.007. Additionally, following the administration of CBZ, serum levels of calcium and sodium were both significantly reduced with P < 0.001 and P = 0.019, respectively. However, alkaline phosphatase levels showed no significant change.
Source: ResultsAbstract: Conclusions
The study outcomes suggest a potential association between long-term CBZ use and bone health, as supported by the presence of biochemical abnormalities. Furthermore, these findings underscore the importance of proactive clinical screening and bone-preserving interventions. Moreover, further studies are recommended to address the management of epilepsy patients with impaired bone health.
Source: ConclusionsAuthors’ abstract
Background
Carbamazepine (CBZ) is a commonly prescribed antiseizure medication frequently prescribed for epilepsy, trigeminal neuralgia, and mood disorders. However, CBZ is a strong inducer of cytochrome P450 enzymes, which can accelerate the catabolism of vitamin D and potentially alter bone metabolism. This study aimed to evaluate the effects of long-term CBZ administration on bone health in patients with epilepsy.
Methods
An observational study involving 226 patients was conducted at King Abdulaziz Medical City in Jeddah, Saudi Arabia. We analyzed the pre: and post-treatment serum levels of vitamin D (nmol/L), alkaline phosphatase (U/L), sodium (mmol/L), and calcium (mmol/L) to assess biochemical changes associated with prolonged CBZ therapy.
Results
The analysis of vitamin D revealed a significant decrease after CBZ treatment (mean ± SD= 36.6 ± 15.68 nmol/L) compared to pre-treatment (45 ± 23.25 nmol/L) with a 95% CI of -14.47 to -2.37 and P = 0.007. Additionally, following the administration of CBZ, serum levels of calcium and sodium were both significantly reduced with P < 0.001 and P = 0.019, respectively. However, alkaline phosphatase levels showed no significant change.
Conclusions
The study outcomes suggest a potential association between long-term CBZ use and bone health, as supported by the presence of biochemical abnormalities. Furthermore, these findings underscore the importance of proactive clinical screening and bone-preserving interventions. Moreover, further studies are recommended to address the management of epilepsy patients with impaired bone health.
Supplementary Information
The online version contains supplementary material available at 10.1186/s42494-026-00262-6.
Publication and source details
Original title: Long-term effects of carbamazepine on bone-related biochemical markers in patients with epilepsy
Alqassem Y. Hakami; Azzam A. Althagafi; Abdulla S. Alkhayat; Belal A. Alturkistani; Hesham E. Mawar; Ibrahim H. Ibrahim; Haneen Abualhamail; Mohamed Eldigire Ahmed
Acta Epileptologica · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:22:44.200048+00:00
DOI: 10.1186/s42494-026-00262-6 · PMC13227868